Previous Article | Next Article ![]()
Clinical and Diagnostic Laboratory Immunology, January 1999, p. 45-49, Vol. 6, No. 1
Department of Clinical
Immunology1 and
Department of
Cardiology,2 University of Groningen, 9713 GZ Groningen, The Netherlands, and
Department of Laboratory
Medicine, University of Graz, A-8010 Graz,
Austria3
Received 25 June 1998/Returned for modification 4 September
1998/Accepted 27 October 1998
Possible causal relations between prior human cytomegalovirus
(HCMV) infection and atherosclerosis and between HCMV reactivation and
restenosis after coronary angioplasty have been suggested. We
investigated patterns of antibodies directed to HCMV in 112 patients
undergoing percutaneous transluminal coronary angioplasty (PTCA) and in a group of sex- and age-matched controls (blood donors
without evidence of atherosclerosis). Levels of antibodies to HCMV were
measured by enzyme-linked immunosorbent assay (ELISA) of serum samples
drawn before and 5 weeks after PTCA. To further differentiate the
humoral immune response, we specifically tested antibody reactivity
towards four single HCMV proteins (IE2, p52, pp150, and pp65) by
recombinant ELISAs. We found that 73% of PTCA patients and 69% of
sex- and age-matched controls were seropositive for HCMV (odds ratio,
1.2 [not significant]). The corresponding odds ratios for matched
pairs ranged in the recombinant ELISAs from 1.2 to 1.4. Patients had
more often high titers of anti-HCMV antibodies (11 versus 4%; odds
ratio = 3.3 [0.9 to 15.2]; P = 0.052) and high
titers of anti-pp150 antibodies (13 versus 4%; odds ratio = 6.0 [1.3 to 38.8]; P = 0.008). Anti-HCMV immunoglobulin M antibodies were not detected in any patient. There was no evidence of
acute HCMV reactivation after PTCA, since the titers of antibodies to
the investigated recombinant proteins did not increase at 5 weeks after
PTCA. Our results show a limited association between prior HCMV
infection and coronary artery disease. We infer that positive anti-HCMV
titers are not a major risk factor at the time of disease
manifestation. However, this study cannot rule out a possible role of
HCMV at earlier stages of the atherosclerotic process. Recombinant
ELISAs provide a valuable tool for investigating the antiviral immune response.
1071-412X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Humoral Immune Response to Human Cytomegalovirus in
Patients Undergoing Percutaneous Transluminal Coronary
Angioplasty

*
Corresponding author. Present address: Department of
Laboratory Medicine, University of Graz, Auenbruggerplatz 15, A-8010 Graz, Austria. Phone: 43 (316) 385-3239. Fax: 43 (316) 385-3430. E-mail: andreas.tiran{at}kfunigraz.ac.at.
Present address: Institute of Medical Biochemistry, University of
Graz, Austria.
This article has been cited by other articles:
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. | Infect. Immun. |
|---|---|---|
| J. Clin. Microbiol. | J. Virol. | ALL ASM JOURNALS |